HomeCompareKANKF vs ABBV

KANKF vs ABBV: Dividend Comparison 2026

KANKF yields 3.32% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $73.4K in total portfolio value
10 years
KANKF
KANKF
● Live price
3.32%
Share price
$30.28
Annual div
$1.01
5Y div CAGR
10.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.9K
Annual income
$1,232.85
Full KANKF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KANKF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKANKFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KANKF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KANKF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KANKF
Annual income on $10K today (after 15% tax)
$282.20/yr
After 10yr DRIP, annual income (after tax)
$1,047.92/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,008.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KANKF + ABBV for your $10,000?

KANKF: 50%ABBV: 50%
100% ABBV50/50100% KANKF
Portfolio after 10yr
$65.6K
Annual income
$13,002.31/yr
Blended yield
19.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KANKF
No analyst data
Altman Z
2.1
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KANKF buys
0
ABBV buys
0
No recent congressional trades found for KANKF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKANKFABBV
Forward yield3.32%3.06%
Annual dividend / share$1.01$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR10.2%40.6%
Portfolio after 10y$28.9K$102.3K
Annual income after 10y$1,232.85$24,771.77
Total dividends collected$7.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KANKF vs ABBV ($10,000, DRIP)

YearKANKF PortfolioKANKF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,066$365.87$11,550$430.00$484.00ABBV
2$12,257$416.97$13,472$627.96$1.2KABBV
3$13,591$475.69$15,906$926.08$2.3KABBV
4$15,086$543.22$19,071$1,382.55$4.0KABBV
5$16,763$620.99$23,302$2,095.81$6.5KABBV
6$18,647$710.65$29,150$3,237.93$10.5KABBV
7$20,766$814.17$37,536$5,121.41$16.8KABBV
8$23,154$933.83$50,079$8,338.38$26.9KABBV
9$25,847$1,072.33$69,753$14,065.80$43.9KABBV
10$28,889$1,232.85$102,337$24,771.77$73.4KABBV

KANKF vs ABBV: Complete Analysis 2026

KANKFStock

Kaneka Corporation manufactures and sells polyvinyl chloride (PVC), crosslinked PVC, PVC-PVAc polymers, paste PVC, acryl grafted-vinyl chloride copolymer, and chlorinated PVC in Japan and internationally. It provides impact modifiers, processing aids, specialty additives, toughener for thermosetting resins, silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, and biodegradable polymer, engineering resin for injection molding, zero birefringence, acrylic film, and isobutylene-based thermoplastic elastomer products. The company also offers polypropylene and kanelite foams, extruded polystyrene foam insulation, polyimide film, transparent film for optical use, high thermal conductive graphite sheets, multi-layer insulation, transparent conductive film, and thermo-resistant, and light-resistant transparent resin products. In addition, it provides photovoltaic power generation systems for residences, public, and industrial installations; eco fur, flame-retardant, hair accessory, and new materials; organic EL lighting panels; and biosurfactant. Further, the company offers intervention, blood purification, gastroenterology intervention, testing equipment, regenerative medicine and cell therapy, and genetic diagnostic products; and low molecular pharmaceutical materials, affinity chromatography resin for purification of a monoclonal antibody, biopharmaceuticals, transdermal medicine, and innerwear with shock-absorbing pad. It also provides dairy products, margarine, fat and oils, whipping cream, filling, baker's yeast/ dough improver, processed fruits, butter, shortening, cacao butter alternatives, cream for kneading and other uses, frozen dough, spices, antifreeze materials; and pharma and supplemental nutrition solutions, including coenzyme, lactic-acid bacteria, and functional foodstuffs, as well as fertilizers. Kaneka Corporation was incorporated in 1949 and is headquartered in Tokyo, Japan.

Full KANKF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KANKF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KANKF vs SCHDKANKF vs JEPIKANKF vs OKANKF vs KOKANKF vs MAINKANKF vs JNJKANKF vs MRKKANKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.